1030 Massachusetts Avenue
About Kyn Therapeutics
Kyn Therapeutics is building a new generation of immuno-oncology therapies targeting powerful immunosuppressive metabolic networks. We envision a future where immunotherapies are the foundation of every cancer patient's treatment, delivering rapid and durable responses.
The Kyn team is composed of drug hunters, translational researchers and entrepreneurs drawn from many of the largest innovators in biotechnology supported by world-class advisors, and is backed by a seasoned board of directors anchored by OrbiMed Healthcare Fund Management and Atlas Venture.
Kyn Therapeutics is headquartered in the biotech hub of Cambridge, Massachusetts.
President and CEO: Mark Manfredi, PhD
VP, R&D: Michelle Zhang, PhD
VP, Drug Discovery: Karen McGovern, PhD
SVP, Chemistry and Preclinical Development: Alfredo Castro PhD
SVP, R&D: Jeffrey Ecsedy, PhD
Head of CMC Operations: James Nolan
Please click here for Kyn Therapeutics' pipeline
8 articles with Kyn Therapeutics
5/10/2019Pharma and biotech companies strengthen their leadership teams with new hires at Immunocore, Eisai, Kyn, Bicycle, and more.
Kyn Therapeutics, a clinical-stage biotechnology company developing highly differentiated cancer immunotherapies, today announced the appointment of Jeffrey Ecsedy, Ph.D., as its chief scientific officer and Jason Sager, M.D., as its chief medical officer.
Kyn Therapeutics today announced that it is expanding its management team with the appointment of Douglas Carlson as its chief financial officer.
Kyn Therapeutics Enters into Global Strategic Collaboration with Celgene to Develop Immuno-oncology Therapies
- Celgene gains exclusive options to two Kyn therapeutic programs
Ahead of being absorbed by Bristol-Myers Squibb, Celgene forged a strategic collaboration with two companies to develop immuno-oncology treatments and cell therapies.
Kyn Therapeutics Announces Initiation of Phase 1b/2 Clinical Studies of ARY-007 in Collaboration with Merck
Two studies to evaluate ARY-007 in combination with KEYTRUDA® (pembrolizumab) in checkpoint-resistant solid tumors
Ronald Renaud to serve as chairman of Kyn’s board of directors
Investors were Atlas Venture and OrbiMed.